Bailard’s Antares Pharma, Inc. ATRS Stock Holding History

Bailard’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-51,900	Closed	-$189K	–	807
2021 Q3	$189K	Buy	+51,900	New	+$210K	0.01%	689

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Bailard's ATRS Position: Q4 2021 in Review

Bailard sold out of Antares Pharma, Inc. (ATRS) in Q4 2021, closing a stake of 51,900 shares — an estimated $189K sold.

Bailard first reported a position in ATRS in Q3 2021 and held it in 1 quarter. The position peaked at $189K in Q3 2021. 162 funds tracked by Wall St. Rank hold ATRS as of Q4 2021.

Bailard reported no remaining Antares Pharma, Inc. position as of Q4 2021 after selling out during the quarter.
Bailard sold 51,900 Antares Pharma, Inc. shares in Q4 2021, an estimated $189K.
Bailard first reported a position in Antares Pharma, Inc. in Q3 2021 and held it in 1 quarter.
Bailard's Antares Pharma, Inc. position peaked at $189K in Q3 2021.
162 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.